Raleigh-based pharma firm Sagent will soon be cutting jobs

RALEIGH – Sagent Pharmaceuticals is cutting 81 jobs at its North Raleigh facility, according to a layoff notice filed with the state of North Carolina.

The layoffs will occur on Aug. 11, the company says.

Sagent develops, manufactures, packages and markets pharmaceutical products with an emphasis on injectables. Its Raleigh site produces sterile injectables and lyophilized formulations of biosimilars, according to the North Carolina Biotechnology Center.

The company is based in Illinois. It has some 440 workers, according to Zippia.com.

Sagent acquired the FDA-approved facility in 2014, the NC Biotech Center reported.

Sargent is owned by the Nichi-Iko Group Company in Tokyo. It focuses on producing, sourcing and marketing injectable medicines for the North American market. Nichi-Iko is one of the largest generic drug manufacturers in Japan.

The 100-acre site adjacent to Capital Boulevard included a 10,000-square-foot laboratory and a separate 70,000-sqare-foot production building at the time of the acquisition.

Five layoff notices have been filed so far this year in Wake County.

Across the state a total of 42 notices affecting more than 3,500 workers.

The post Raleigh-based pharma firm Sagent will soon be cutting jobs first appeared on WRAL TechWire.

biosimilars
pharmaceuticals
biotech
pharma
fda
markets